In particular, EGFR targeting monoclonal antibody cetuximab was approved for the treatment of late-stage HNSCC, while the anti-programmed death-1 (PD-1) immune checkpoint inhibitors nivolumab and pembrolizumab were both approved for the treatment of patients with recurrent or metastatic HNSCC [6]. Here, EGFR is linked to head and neck squamous cell carcinoma.